“We have already adopted the strategy of a checkpoint inhibitor [pembrolizumab] after chemoradiation for stage ... tertiary ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).

The FDA approved Keytruda (pembrolizumab), which is a PD-1 inhibitor ... Hodgkin lymphoma may have already been taking the ...

The trial will enrol patients with mCRC who are microsatellite stable (MSS), wild type (WT) RAS, WT BRAF, and human epidermal ...

A 2020 open-label, phase 2 study, for instance, found that pembrolizumab demonstrated activity in brain metastases in about 30% of patients (11 of 37) with untreated or previously treated stable brain ...

Exelixis develops and commercializes new molecular entities to treat cancer. Its flagship product, cabozantinib, is marketed ...

EV-302 is an ongoing, open-label, randomized, controlled Phase 3 trial, evaluating enfortumab vedotin in combination with pembrolizumab versus platinum-containing chemotherapy in patients with ...

BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH ...

This open-label NIPPON, JCOG2007 study was conducted ... to receive four cycles of platinum-based chemotherapy plus pembrolizumab or two cycles of platinum-based chemotherapy plus nivolumab ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine ...